The National Pharmaceutical Council’s (NPC) fourth annual survey of health care stakeholders is... Watch Video
NPC at a Glance
NPC is a health policy research organization focused on the critical issues of evidence, the value of medicines for patients, and innovation...more
CER
Do stakeholders think comparative effectiveness research is having an impact on health care decision making? Which organizations are viewed as the leaders on prioritizing, funding, and conducting research? Download our new booklet to find out...more
Value of Rx
Recent NPC research has focused on defining the optimal role and value of pharmaceuticals in the evolving payment and delivery models...more
Individual Treatment Effects
Being "unique" can impact your health care treatments. Learn more about the challenges of individual treatment effects...more
RECENT NEWS
CER Tweets of the Week: Improving Patient Care Remains Hot Topic (July 14 - 18)
Evidence-based medicine (EBM) and the role of big data in improving patient care continued to be hot topics... moreCER Tweets of the Week: Patient-Generated Data, Value-Based Payment Programs & Impact of CER (July 7 - 11)
Which issues attracted comparative effectiveness research (CER) stakeholders’ attention this week in the ... more#TBT: Consumer-Directed Health Plans & Employers’ Decision-Making
As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and... moreCER Tweets of the Week: Evidence-Based Medicine & #PCORI Advisory Panels (June 30th – July 4th)
What was trending among comparative effectiveness research (CER) stakeholders on Twitter this week? Dialogue... more
PCORI Makes Appointments to Advisory Panels, Announces More Funding for Pragmatic Studies
The Patient-Centered Outcomes Research Institute (PCORI) Board of Governors met on June 17 to address a number... moreEarn CE Credits Via CER Collaborative’s Certificate Program on Evaluating Research Findings
Formulary decision-makers are aware that comparative effectiveness research (CER) has the potential for positive... moreEmployers Still Trying to Find Right Strategy for Specialty Drug Benefits, According to Latest MBGH Survey
While almost 75% of employers incentivize for employee use of a specialty pharmacy, there are minimal or no... moreResearchers Explore Challenges in Health Technology Assessment at June Meeting in DC
Health care researchers from around the world gathered in Washington, DC, this month for the Health Technology... more
Specialty Medications: Shifting the Focus From “How Much” We Spend to “How Well” We Spend
Washington, DC, June 9, 2014—As health care decision-makers grapple with how to ensure access to specialty... moreNPC Annual Stakeholder Survey: Comparative Effectiveness Research Is Important, But Impact on Health Care Decision-Making Is Still on the Horizon
(Washington, DC, May 19, 2014)—A new survey of health care stakeholders reveals continued optimism for the use... moreCER Collaborative Improving Health Outcomes Through New Comparative Evidence Tools
(Washington, DC, March 24, 2014)—Three peer-reviewed articles published in Value in Health offer important... moreNPC, Quintiles Study Tests Tools to Evaluate Quality of Observational Research in Comparative Effectiveness Studies
(Washington, DC, February 25, 2014)—With the growing demand for information about comparative effectiveness and... more
Healthcare Leadership Council & NPC Submit Comments to CMS on Access to Part D Data
March 7, 2014The Honorable Marilyn Tavenner, AdministratorCenters for Medicare & Medicaid ServicesU.S.... moreNPC Comments on CMS' Proposed Changes to Protected Classes
March 7, 2014Marilyn B. TavennerAdministratorCenters for Medicare & Medicaid ServicesU.S. Department of... moreThe State of CER and the Environment for Health Care Decision Making
This month, NPC released its third annual survey on stakeholders’ views on comparative effectiveness research (... moreKeeping Our Eye on the CER Ball
Until the cherry blossoms begin to bloom later next month, most of the water cooler conversations in Washington... more
Health Technology Assessments and Specialty Medications
David Grainger, senior director, global public policy, Eli Lilly and Company, says that there are often... moreDifferences in Global Health Technology Assessment
David Grainger, senior director, global public policy, Eli Lilly and Company, describes how health technology... moreIncorporating Patient Views Into Health Technology Assessments
David Grainger, senior director, global public policy, Eli Lilly and Company, explains that many health... moreReal-World Impact of Comparative Effectiveness Research Findings on Clinical Practice
National Pharmaceutical Council Chief Science Officer Robert W. Dubois, MD, PhD, discusses a peer-reviewed study... moreCER Tweets of the Week: Improving Patient Care Remains Hot Topic (July 14 - 18)
Evidence-based medicine (EBM) and the role of big data in improving patient care continued to be hot topics... moreCER Tweets of the Week: Patient-Generated Data, Value-Based Payment Programs & Impact of CER (July 7 - 11)
Which issues attracted comparative effectiveness research (CER) stakeholders’ attention this week in the ... more#TBT: Consumer-Directed Health Plans & Employers’ Decision-Making
As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and... moreCER Tweets of the Week: Evidence-Based Medicine & #PCORI Advisory Panels (June 30th – July 4th)
What was trending among comparative effectiveness research (CER) stakeholders on Twitter this week? Dialogue... moreNEWS FEEDS
WEBINAR
Consumer-Directed Health Plans: Pharmacy Benefits & Best Practices
NPC will share survey results of 96 large and jumbo employers about their current benefit practices, and the best practices developed based on the results.
July 23, 2014
1 pm – 2 pm ET
NEWS
CER Is Important, But Impact Is Still on the Horizon
“The survey provides an important look at how perceptions of CER have shifted during the implementation of the Affordable Care Act.” —NPC Director of Health Services Research Kimberly Westrich
